US pharmaceutical giant Eli Lilly has reached a deal worth $2.75 billion with Insilico Medicine. Under the agreement, Lilly will bring AI-developed drugs to the global market, while Insilico will receive $115 million upfront, with the remainder tied to regulatory approvals and commercial milestones
Recent Posts
- Powerica IPO Allotment Today: Steps To Check Status, Latest GMP, Listing Date And More
- Michael Saylor Spent A Decade Doing ‘Everything Under The Sun,’ But Still Couldn’t ‘Get Ahead’ — Success Hit When He Understood This One Thing
- Stablecoin payments go ‘invisible’ in Southeast Asia as crypto card business surges
- Walmart-backed OnePay adds tokens in push to serve ‘new to crypto’ customers
- Strategy may have paused bitcoin accumulation last week, ending a thirteen week buying streak